CAS: 6344-72-5; 6-Methylquinoxaline

相似化合物

23088-24-6 442517-33-1 13708-12-8

上下游产品

CAS号517-21-5 乙二醛亚硫酸氢钠水合物 | CAS号496-72-0 3,4-二氨基甲苯 | CAS号107-21-1 乙二醇 | CAS号20304-86-3 5-甲基-2,1,3-苯并噁二唑 | CAS号141-43-5 2-氨基乙醇 | CAS号89-62-3 4-甲基-2-硝基苯胺 | CAS号6639-93-6 6-甲基-1,2,3,4-四氢喹啉 | CAS号81429-46-1 1-phenyl-5-p-to... | CAS号7732-18-5 水 | CAS号53967-21-8 6-溴甲基喹喔啉 | CAS号488834-75-9 (喹噁啉-6-基)甲醇 | CAS号130345-50-5 6-喹喔啉甲醛 | CAS号17635-21-1 2,3,6-三甲基喹喔啉 | CAS号6639-93-6 6-甲基-1,2,3,4-四氢喹啉 | CAS号477776-17-3 6-(氯甲基)喹喔啉 | CAS号488834-74-8 N-(quinoxalin-6...

1,2,3,4-四氢-6-甲基喹噁啉置于potassium Tert-Butylate体系中,用 邻二甲苯 作为反应溶剂,化学反应 36.0H,以93%的收率获得产物6-甲基喹喔啉
参考文献:叔丁醇钾促进的n-杂环无受体脱氢
标题:叔丁醇钾促进的n-杂环无受体脱氢
摘要:钾叔n-杂环的丁醇促进的acceptorless脱氢高效地实现用于n-杂芳烃和氢气的过渡金属-自由条件下产生.在存在ko T Bu碱的情况下,各种六元和五元n-杂环化合物可以有效地进行无受体脱氢,从而在140oc的邻二甲苯中提供相应的n-杂芳烃和h 2气体.本协议提供了一条通往芳香族含氮化合物和h 2气体的便捷途径.
DOI:10.1002/adsc.201900499

专利信息

专利号:US-2004101523-A1
优先权日:1989-07-27
标题:Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension
发明人：REITZ DAVID B; KOEPKE JOHN P; BLAINE EDWARD H; SCHUH JOSEPH R; MANNING ROBERT E; SMITS GLENN J
权利人:SEARLE & CO
摘要:Renal-selective prodrugs are described which are preferentially converted in the kidney to compounds capable of inhibiting synthesis of catecholamine-type neurotransmitters involved in renal sympathetic nerve activity. The prodrugs described herein are derived from inhibitor compounds capable of inhibiting one or more of the enzymes involved in catecholamine synthesis, such compounds being classifiable as tyrosine hydroxylase inhibitors, or as dopa-decarboxylase inhibitors, or as dopamine-β-hydroxylase inhibitors. These inhibitor compounds are linked to a chemical moiety, such as a glutamic acid derivative, by a cleavable bond which is recognized selectively by enzymes located predominantly in the kidney. The liberated inhibitor compound is then available in the kidney to inhibit one or more of the enzymes involved in catecholamine synthesis. Inhibition of renal catecholamine synthesis can suppress heightened renal nerve activity associated with sodium-retention related disorders such as hypertension. Conjugates of particular interest are glutamyl derivatives of dopamine-β-hydroxylase inhibitors, of which N-acetyl-γ-glutamyl fusaric acid hydrazide (shown below) is preferred.

专利号:WO-2017004172-A1
优先权日:2015-06-29
标题:Total synthesis of shishijimicin a and analogs thereof

专利号:US-10233182-B2
优先权日:2014-04-04
标题 :Substituted spirocyclic inhibitors of autotaxin
发明人：BABISS LEE; CLARK MATTHEW; KEEFE ANTHONY D; MULVIHILL MARK J; NI HAIHONG; RENZETTI LOUIS; RUEBSAM FRANK; WANG CE; XIE ZHIFENG; ZHANG YING
权利人:X RX INC
摘要:The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases, thrombosis, and cholestatic pruritus, mediated at least in part by ATX.

专利号:CN-113828342-A
优先权日:2021-09-30
标 题:Cu-Pd-CeO2/γ-Al2O3Preparation of @ NP catalyst and synthesis of benzopyrazine compounds

专利号:CN-113828342-B
优先权日:2021-09-30
标题 :Preparation of Cu-Pd-CeO2/γ-Al2O3@NP catalyst and synthesis of benzopyrazine compounds

专利号:WO-2022202643-A1
优先权日:2021-03-23
标 题:Method for producing s,s-(6-methylquinoxaline-2,3-diyl)dithiocarbonate
发明人：SHIGENOBU MASASHI; FUJIMOTO RYOSUKE; OKITA CHIAKI
权利人:OSAKA SODA CO LTD
摘要:The purpose of the present invention is to provide a method for producing high-purity S,S-(6-methylquinoxaline-2,3-diyl)dithiocarbonate by efficiently removing starting materials used for the synthesis and specific impurities produced during the synthesis from S,S-(6-methylquinoxaline-2,3-diyl)dithiocarbonate. The present invention provides a method for producing S,S-(6-methylquinoxaline-2,3-diyl)dithiocarbonate, the method comprising: a step (reaction step) in which 2,3-dimercapto-6-methylquinoxaline is converted into an alkali metal salt or an alkaline earth metal salt, and is subsequently reacted with a phenyl chloroformate in the presence of a phase-transfer catalyst; and a purification step which is characterized by purifying S,S-(6-methylquinoxaline-2,3-diyl)dithiocarbonate with use of an acetic acid ester, the S,S-(6-methylquinoxaline-2,3-diyl)dithiocarbonate having been obtained by the reaction.